Join the club for FREE to access the whole archive and other member benefits.

Adam Freund

Principal Investigator at Calico

Adam has studied aspects of the biology of aging throughout his career. His graduate work with Judy Campisi at the University of California at Berkeley and the Buck Institute focused on the regulation of inflammatory networks during cellular senescence. He then did postdoctoral work with Steven Artandi at Stanford University, where he developed high content screening methods to identify regulators of telomerase.


Visit website:


See also: Company Calico - Combating aging and associated diseases. An Alphabet (Google) subsidiary.

Details last updated 04-Sep-2020

Adam Freund News

Arda Therapeutics, new biotech startup aims to delay or reverse disease progression (LEAF) - 28-Jan-2022

Tailoring strategies to eliminate bad cells in age-related diseases


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


Longevity.Technology interviews Adam Freund - Calico’s Principal Investigator

Longevity Technology - 02-Sep-2020

Will be presenting a viable therapeutic strategy using IGF signaling at ARDD 2020